Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ketoconazole 400 Clear all

Conditions: Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
Interventions: Fenretinide/LXS + Ketoconazole; Drug
Lead sponsor: South Plains Oncology Consortium; Network
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas

Conditions: Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions: ketoconazole, gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nonhematologic Malignancies, Lymphoma
Interventions: Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: Degarelix, Doxorubicin, Ketoconazole, Docetaxel, Estramustine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: ketoconazole-placebo, placebo-ketoconazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Prostatic Neoplasms
Interventions: Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: ketoconazole, hydrocortisone, dutasteride, lapatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: SB-751689 oral tablets (100 and 400 ng), Ketoconazole (NIZORAL) oral tablets (200 mg); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions: NKTR-118, Ketoconazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Bilastine, Bilastine & Ketoconazole, Moxifloxacin, Placebo; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: ketoconazole, casopitant 100 mg, Casopitant 50 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Alzheimer Disease
Interventions: BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole, Fluconazole, BMS-708163 + Fluconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharmacokinetics
Interventions: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: HCV Infection
Interventions: ABT-072, ketoconazole, Placebo; Drug · Other
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Gastroparesis
Interventions: GSK962040, Ketoconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Neoplasms
Interventions: brentuximab vedotin, rifampin, midazolam, ketoconazole; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Duarte, California • Denver, Colorado • Indianapolis, Indiana + 3 more

Conditions: Prostate Cancer
Interventions: ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 120 Years · Male only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Minneapolis, Minnesota

Conditions: Obstetric Labour, Premature
Interventions: GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
Interventions: NBI-98854 50 mg capsule once daily, Ketoconazole 400 mg (200 mg twice daily); Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Males
Interventions: Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: JTK-853, ketoconazole, JTK-853 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 3
States / cities: Overland Park, Kansas • Buffalo, New York • Columbus, Ohio

Conditions: Cancer
Interventions: pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Greenville, South Carolina

Search by objective public record fields.

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Investigating the Regulation of Reproductive Hormones in Adult Men

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

GSK962040 Drug-drug Interaction Study With Ketoconazole

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK